Why the study?
Does a rivaroxaban-based antithrombotic strategy prevent subclinical leaflet-motion abnormalities compared to an antiplatelet-based strategy in patients without an indication for long-term anticoagulation who have undergone successful TAVR?
Does a rivaroxaban-based antithrombotic strategy prevent subclinical leaflet-motion abnormalities compared to an antiplatelet-based strategy in patients without an indication for long-term anticoagulation who have undergone successful TAVR?
While a rivaroxaban-based strategy reduces subclinical leaflet-motion abnormalities after TAVR, it is associated with higher risks of death, thromboembolic complications, and bleeding compared to an antiplatelet-based strategy.
No takes yet. Share an insight, caveat, or question.
Does not support rivaroxaban post-TAVR despite fewer leaflet abnormalities; challenges imaging surrogates given main-trial harms.
Backer et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: